

APPENDIX

The AGREE II instrument

Adapted from: Brouwers MC, Kerkvliet K, Spithoff K. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. *BMJ*. 2016;i1152.

Domains	Items	Assessment*
I. Scope and purpose	1. The overall objective(s) of the guideline is (are) specifically described.	1 to 7
	2. The health question(s) covered by the guideline is (are) specifically described.	1 to 7
	3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.	1 to 7
II. Stakeholder involvement	4. The guideline development group includes individuals from all relevant professional groups.	1 to 7
	5. The views and preferences of the target population (patients, public, etc.) have been sought.	1 to 7
	6. The target users of the guideline are clearly defined.	1 to 7
III. Rigor of development	7. Systematic methods were used to search for evidence.	1 to 7
	8. The criteria for selecting the evidence are clearly described.	1 to 7
	9. The strengths and limitations of the body of evidence are clearly described.	1 to 7
	10. The methods for formulating the recommendations are clearly described.	1 to 7
	11. The health benefits, side effects, and risks have been considered in formulating the recommendations.	1 to 7
	12. There is an explicit link between the recommendations and the supporting evidence.	1 to 7
	13. The guideline has been externally reviewed by experts prior to its publication.	1 to 7
	14. A procedure for updating the guideline is provided.	1 to 7

IV. Clarity of presentation	15. The recommendations are specific and unambiguous.	1 to 7
	16. The different options for management of the condition or health issue are clearly presented.	1 to 7
	17. Key recommendations are easily identifiable.	1 to 7
V. Applicability	18. The guideline describes facilitators and barriers to its application.	1 to 7
	19. The guideline provides advice and/or tools on how the recommendations can be put into practice.	1 to 7
	20. The potential resource implications of applying the recommendations have been considered.	1 to 7
	21. The guideline presents monitoring and/or auditing criteria.	1 to 7
VI. Editorial independence	22. The views of the funding body have not influenced the content of the guideline.	1 to 7
	23. Competing interests of guideline development group members have been recorded and addressed.	1 to 7
Overall guideline assessment	24. Rate the overall quality of this guideline.	1 to 7
	25. I would recommend this guideline for use.	<ul style="list-style-type: none"> • Yes • Yes, with modifications • No
* 7 corresponds to the highest possible quality.		